ISORAY INVESTORS: Lieff Cabraser Announces Class Action Litigation Against IsoRay, Inc. - ISR

SAN FRANCISCO--(BUSINESS WIRE)-- The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of investors who purchased the securities of IsoRay, Inc. (“IsoRay” or the “Company”) (NYSE: ISR) between May 20, 2015 and May 21, 2015, inclusive (the “Class Period”).

If you purchased IsoRay securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than July 21, 2015. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

IsoRay investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the IsoRay Securities Class Litigation

The actions charge IsoRay and certain of its officers with violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934. IsoRay develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.

The actions allege that defendants made false and/or misleading statements regarding IsoRay’s Cesium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers. On May 20, 2015, IsoRay issued a press release touting the on-line publication of a study purportedly showing improved results using IsoRay’s Cesium-131 seeds in the treatment of lung cancer.

On May 21, 2015, TheStreet.com published an article about IsoRay, arguing that the Company had selectively edited findings from the study in order to make its Cesium-131 product appear better than it actually is. On this news, the price of IsoRay common stock fell $1.10 per share, or 35.25%, from a closing price of $3.12 on May 20, 2015, to close at $2.02 per share on May 21, 2015, on extremely heavy trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for eleven years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity.” Best Lawyers and U.S. News have also named Lieff Cabraser as a “Law Firm of the Year” each year the publications have given this award to law firms.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602007052/en/

Source/Contact for Media Inquiries Only:
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 1-800-541-7358

Source: Lieff Cabraser Heimann & Bernstein, LLP

You May Also Be Interested In

• Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
• SPACEMOBILE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AST SpaceMobile, Inc. and Encourages Investors to Contact the Firm
• SKT collaborates with Aptos Labs, Brevan Howard and Microsoft to bring global institutional finance on-chain with Aptos Ascend